A rare case of superior ophthalmic vein thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccine against SARS-CoV-2

Panovska-Stavridis, Irina

doi:10.4084/mjhid.2021.048

Cited by 27 publications

(18 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 52 This section focuses on superior ophthalmic vein thrombosis, as reported in two isolated cases. 21 , 58 Both patients received the ChAdOx1 nCoV-19 vaccine. Panovska-Stavridis et al .…”

Section: Amnmentioning

confidence: 99%

See 1 more Smart Citation

Ocular Adverse Events After COVID-19 Vaccination

Betzler

Testi

et al. 2021

Ocular Immunology and Inflammation

157

119

View full text Add to dashboard Cite

Purpose The COVID-19 pandemic has galvanized the development of new vaccines at an unprecedented pace. Since the widespread implementation of vaccination campaigns, reports of ocular adverse effects after COVID-19 vaccinations have emerged. This review summarizes ocular adverse effects possibly associated with COVID-19 vaccination, and discusses their clinical characteristics and management. Methods Narrative Literature Review. Results Ocular adverse effects of COVID-19 vaccinations include facial nerve palsy, abducens nerve palsy, acute macular neuroretinopathy, central serous retinopathy, thrombosis, uveitis, multiple evanescent white dot syndrome, Vogt-Koyanagi-Harada disease reactivation, and new-onset Graves’ Disease. Studies in current literature are primarily retrospective case series or isolated case reports – these are inherently weak in establishing association or causality. Nevertheless, the described presentations resemble the reported ocular manifestations of the COVID-19 disease itself. Hence, we hypothesize that the human body’s immune response to COVID-19 vaccinations may be involved in the pathogenesis of the ocular adverse effects post-COVID-19 vaccination. Conclusion Ophthalmologists and generalists should be aware of the possible, albeit rare, ocular adverse effects after COVID-19 vaccination.

show abstract

“… 52 This section focuses on superior ophthalmic vein thrombosis, as reported in two isolated cases. 21 , 58 Both patients received the ChAdOx1 nCoV-19 vaccine. Panovska-Stavridis et al .…”

Section: Amnmentioning

confidence: 99%

“…Panovska-Stavridis et al . 58 describe a 29-year-old female who presented with severe headache, orbital swelling with proptosis, limited ocular motility, vertical diplopia, and reduced visual acuity 10 days after the first dose. Initial findings showed thrombocytopenia of 18 × 10 9 /L and high D-dimer levels of 35712 μg/L.…”

Section: Amnmentioning

confidence: 99%

Ocular Adverse Events After COVID-19 Vaccination

Betzler

Testi

et al. 2021

Ocular Immunology and Inflammation

157

119

View full text Add to dashboard Cite

show abstract

“…Ultimately the patient was treated with anticoagulation and discharged. Elsewhere, Panovska-Stavridis et al reported on a case of a 29-year-old woman (Figure 1) who developed left orbital swelling, severe headache, and blurred left eye vision 10 days after receiving the AZD1222 vaccine [20]. MRI imaging demonstrated central filling defects and a diagnosis of superior ophthalmic vein thrombosis was made.…”

Section: Superior Ophthalmic Vein Thrombosismentioning

confidence: 99%

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

et al. 2022

View full text Add to dashboard Cite

Vaccination efforts as a mitigation strategy in the corona virus disease 2019 (COVID-19) pandemic are fully underway. A vital component of understanding the optimal clinical use of these vaccines is a thorough investigation of adverse events following vaccination. To date, some limited reports and reviews have discussed ocular adverse events following COVID-19 vaccination, but a systematic review detailing these reports with manifestations and clinical courses as well as proposed mechanisms has yet to be published. This comprehensive review one-year into vaccination efforts against COVID-19 is meant to furnish sound understanding for ophthalmologists and primary care physicians based on the existing body of clinical data. We discuss manifestations categorized into one of the following: eyelid, orbit, uveitis, retina, vascular, neuro-ophthalmology, ocular motility disorders, and other.

show abstract

“…Bayas et al reported a case of bilateral superior ophthalmic vein thrombosis, ischemic stroke, and thrombocytopenia after ChAdOx1 nCoV-19 (AstraZeneca) vaccination, and other unilateral case reports have also been published. [105][106][107] Acute macular neuroretinopathy has been reported following the ChAdOx1 nCoV-19 vaccination, 108,109 and CNVI palsy has been reported 2 days after BNT162b2 mRNA vaccine (Pfizer), which resolved after 3 months. 110 Fan et al reported a case of branched retinal artery occlusion with features of paracentral acute middle maculopathy in a pediatric patient after BNT162b2 vaccination (personal communication).…”

Section: Potential Systemic and Ocular Side Effectsmentioning

confidence: 99%

Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare

Leung¹,

Fan²,

Flynn³

et al. 2022

OPTH

View full text Add to dashboard Cite

There is increasing information available about the effects of the SARS-CoV-2 virus on the systemic and ocular health of patients, as well as the effects of delayed health care. This mini-review summarizes the potential complications and treatments of COVID-19. Systemic findings include respiratory illness, risk of thromboembolic events, and neurologic findings. Some patients may develop persistent symptoms even after the infection resolves. Effective treatment options include glucocorticoids, antivirals, interleukin-6 antagonists, monoclonal antibodies, Janus kinase inhibitors and vaccines. Potential ocular findings of COVID-19 include conjunctivitis, cranial nerve palsies, and microvascular changes in the retina; most symptoms resolved over time. During the lockdown periods, teleophthalmology was utilized to triage non-urgent issues; patients who did present to emergency departments tended to have more severe disease with worse visual prognoses. While transient delays in outpatient ophthalmic care may be tolerated in some patients, others experienced significant vision loss with interruptions in treatments. Resumption of ophthalmic care as soon as possible may help mitigate the effects of delayed care due to the pandemic.

show abstract

A rare case of superior ophthalmic vein thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccine against SARS-CoV-2

Abstract: x

Cited by 27 publications

References 5 publications

Ocular Adverse Events After COVID-19 Vaccination

Ocular Adverse Events After COVID-19 Vaccination

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare

Contact Info

Product

Resources

About